Loading...
Loading...
Duality Biotherapeutics Inc/ADR
Duality Biotherapeutics Inc/ADR. Spoken Alpha tracks DUTBF's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks DUTBF's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 90% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 3 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for DUTBF.
curl https://api.spokenalpha.com/v1/companies/DUTBF| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $3.55 | $3.51 | +1.1% | +2.3% | +3.1% |
| Q4 FY2026 | $3.73 | $3.52 | +6.0% | +9.0% | +8.8% |
| Q3 FY2026 | $4.45 | $3.82 | +16.6% | +4.4% | +1.5% |
| Q2 FY2026 | $3.88 | $3.72 | +4.2% | +9.1% | +7.6% |
| Q1 FY2025 | $3.81 | $3.67 | +3.9% | +7.1% | +5.3% |
| Q4 FY2025 | $4.11 | $3.88 | +5.8% | -1.7% | -3.1% |
| Q3 FY2025 | $3.82 | $3.65 | +4.7% | +5.9% | +3.6% |
| Q2 FY2025 | $4.29 | $3.85 | +11.4% | +6.0% | +4.2% |
| Q1 FY2024 | $4.43 | $3.79 | +16.8% | +8.4% | +7.9% |
| Q4 FY2024 | $4.28 | $3.88 | +10.2% | +5.9% | +8.5% |